Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PrefHER: SC vs IV Trastuzumab Preference Study
NCT01401166Phase 2Completed
- Sponsor
- Roche
- Start
- Oct 2011
- Primary completion
- May 2013
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 2 trial of trastuzumab in HER2-positive breast cancer, sponsored by Roche. Started Oct 2011; status: completed.
02
Drugs
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT01401166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01401166.